ProShare Advisors LLC Reduces Position in Savara Inc (NASDAQ:SVRA)

ProShare Advisors LLC decreased its holdings in shares of Savara Inc (NASDAQ:SVRA) by 19.8% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,630 shares of the company’s stock after selling 5,085 shares during the quarter. ProShare Advisors LLC’s holdings in Savara were worth $83,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Wellington Management Group LLP purchased a new stake in shares of Savara in the fourth quarter valued at about $9,683,000. Opaleye Management Inc. purchased a new stake in shares of Savara in the first quarter valued at about $4,258,000. Superstring Capital Management LP purchased a new stake in shares of Savara in the fourth quarter valued at about $3,827,000. Janus Henderson Group PLC grew its holdings in shares of Savara by 41.1% in the first quarter. Janus Henderson Group PLC now owns 2,563,620 shares of the company’s stock valued at $12,754,000 after purchasing an additional 746,407 shares during the period. Finally, Bain Capital Life Sciences Investors LLC grew its holdings in shares of Savara by 2.3% in the first quarter. Bain Capital Life Sciences Investors LLC now owns 14,565,457 shares of the company’s stock valued at $72,536,000 after purchasing an additional 332,706 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have commented on SVRA shares. Guggenheim upped their target price on shares of Savara from $8.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Oppenheimer upped their target price on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday, June 26th. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research report on Tuesday, October 1st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Savara in a research report on Tuesday, October 1st. Six research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $11.17.

Savara Stock Down 2.1 %

Shares of NASDAQ:SVRA opened at $3.74 on Tuesday. The firm’s 50 day moving average price is $4.28 and its 200 day moving average price is $4.43. The stock has a market cap of $516.83 million, a price-to-earnings ratio of -10.11 and a beta of 0.96. Savara Inc has a fifty-two week low of $3.12 and a fifty-two week high of $5.70. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26.

Savara (NASDAQ:SVRA) last issued its earnings results on Monday, August 12th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.01). As a group, equities research analysts predict that Savara Inc will post -0.44 earnings per share for the current fiscal year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.